MALVERN, Pa.--(BUSINESS WIRE)--Fujirebio Diagnostics, Inc., the premier cancer diagnostics company, announced today that the United States Patent and Trademark Office has issued a patent for the HE4 biomarker. The company, which was notified of the patent allowance last June, expects this to be the first of a family of patents for this ovarian cancer biomarker. This patent, covering the measurement of HE4 and antibodies to HE4 in blood, serum and plasma, will allow Fujirebio Diagnostics to continue developing its biomarker for screening, detecting, monitoring and prognosis of ovarian cancer. It also includes claims in which HE4 is used in conjunction with other ovarian cancer markers such as Fujirebio Diagnostics’ CA 125, the industry’s current gold standard for monitoring ovarian cancer.
